98%
921
2 minutes
20
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11706804 | PMC |
http://dx.doi.org/10.1186/s40635-024-00702-y | DOI Listing |
Front Pediatr
June 2025
Expert Microbiology Unit, Department of Health Security, National Institute for Health and Welfare, Helsinki, Finland.
[This corrects the article DOI: 10.3389/fped.2024.
View Article and Find Full Text PDFIntensive Care Med Exp
January 2025
Department of Biomedical Sciences, Humanitas University, Via Levi Montalcini, Pieve Emanuele, MI; 2IRCCS Humanitas Research Hospital, Via Manzoni 56, 20089, Rozzano, Milan, Italy.
Ann Rheum Dis
April 2024
Rheumazentrum Ruhrgebiet, Ruhr University Bochum, Herne, Germany.
Ankylosing spondylitis (AS) is the historic term used for decades for the HLA-B27-associated inflammatory disease affecting mainly the sacroiliac joints (SIJ) and spine. Classification criteria for AS have radiographic sacroiliitis as a dominant characteristic. However, with the availability of MRI of SIJ, it could be demonstrated that the disease starts long before definite SIJ changes become visible on radiographs.
View Article and Find Full Text PDFOptom Vis Sci
May 2023
Department of Ophthalmology, School of Medicine, Kitasato University, Sagamihara, Japan.
Significance: The determination of aniseikonia tolerance may aid in developing optimal treatment plans for cataract surgery, refractive surgery, and refractive correction with glasses and contact lenses.
Purpose: This study aimed to measure aniseikonia tolerance.
Methods: We included 33 patients (mean age ± standard deviation, 28.
JAMA Netw Open
November 2022
National Referral Center for Rare Systemic Autoimmune Diseases, Hôpital Cochin, Assistance Publique-Hôpitaux de Paris (AP-HP) Centre, Université Paris Cité, Paris, France.
Importance: Results of randomized clinical trials have demonstrated rituximab's noninferiority to cyclophosphamide as induction therapy for antineutrophil cytoplasm antibody (ANCA)-associated vasculitides (AAV), with neither treatment having a specific advantage for granulomatosis with polyangiitis (GPA). However, post hoc analysis results have suggested that rituximab might be more effective than cyclophosphamide in inducing remission in patients with proteinase 3-positive AAV.
Objective: To compare the effectiveness of rituximab and cyclophosphamide in inducing GPA remission in a large population of unselected patients.